Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma (ASH 2022) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma
From the ASH Annual Meeting & Exposition

Conference Coverage
Ibrutinib With and Following AutoHCT Well-Tolerated Among Patients With R/R Activated-B-Cell Subtype DLBCL
12/10/2023
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with...
12/10/2023
Oncology
Conference Coverage
Mosunetuzumab Monotherapy Continues to Demonstrate Efficacy, Safety for Elderly/Unfit Patients With DLBCL
12/12/2022
For patients with DLBCL unable to tolerate first-line chemoimmunotherapy, mosunetuzumab monotherapy continues to demonstrate promising efficacy with durable response with manageable safety with longer follow-up.
For patients with DLBCL unable to tolerate first-line chemoimmunotherapy, mosunetuzumab monotherapy continues to demonstrate promising efficacy with durable response with manageable safety with longer follow-up.
For patients with DLBCL unable...
12/12/2022
Oncology
Conference Coverage
Odronextamab Exhibits Clinically Meaningful Efficacy and Manageable Safety in Relapsed/Refractory DLBCL
12/12/2022
Findings from a phase 2 trial show that odronextamab demonstrates clinically meaningful efficacy, durable complete responses, and tolerable safety in patients with relapsed/refractory DLBCL.
Findings from a phase 2 trial show that odronextamab demonstrates clinically meaningful efficacy, durable complete responses, and tolerable safety in patients with relapsed/refractory DLBCL.
Findings from a phase 2 trial...
12/12/2022
Oncology
Conference Coverage
Novel Agents Preferable to Standard Chemotherapy for Salvage Treatment in LBCL Progressing After CAR-T Therapy
12/11/2022
Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.
Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.
Salvage treatment with...
12/11/2022
Oncology
Conference Coverage
Second-Line Polatuzumab Vedotin Plus RICE Yields High Response Rates in Relapsed/Refractory DLBCL
12/11/2022
Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.
Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.
Second-line treatment with...
12/11/2022
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use